tranexamic acid has been researched along with Coagulation Disorders, Blood in 109 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The use of tranexamic acid (TXA) is established in the treatment of bleeding, especially of bleeding due to hyperfibrinolysis." | 9.12 | [Tranexamic acid for bleeding prophylaxis in orthopedic surgery and trauma-standard or customized therapy?] ( Möhnle, P; Pekrul, I; Schachtner, T; Zwißler, B, 2021) |
| "The American Trial Using Tranexamic Acid (TXA) in Thrombocytopenia (A-TREAT, NCT02578901) demonstrated no superiority of TXA over placebo in preventing World Health Organization (WHO) grade 2 or higher bleeding in patients with severe thrombocytopenia requiring supportive platelet transfusion following myeloablative therapy for hematologic disorders." | 8.31 | Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. ( Brown, SP; de Laat, B; El Kassar, N; Gernsheimer, TB; Herren, H; Holle, LA; Ilich, A; Key, NS; Lucas, AT; May, S; Triulzi, DJ; Wolberg, AS, 2023) |
| " Tranexamic Acid (TXA) is used as an anti-fibrinolytic agent to reduce surgical bleeding if administered prior to or during surgery, and to improve survival in trauma if given early after trauma." | 7.91 | Effect of tranexamic acid administration on acute traumatic coagulopathy in rats with polytrauma and hemorrhage. ( Benov, A; Cap, AP; Darlington, DN; Keesee, JD; Liu, B; Wu, X, 2019) |
| " Our purposes were to study the efficacy of tranexamic acid (TXA) and prothrombin complex concentrate (PCC) on a traumatic coagulopathy with a severe native metabolic acidosis and compare the efficacy of PCC versus fresh frozen plasma (FFP) to reverse a dilutional coagulopathy." | 7.79 | The effects of tranexamic acid and prothrombin complex concentrate on the coagulopathy of trauma: an in vitro analysis of the impact of severe acidosis. ( Eckert, M; Izenberg, S; Martin, MJ; McVay, D; Nelson, D; Porta, CR; Salgar, S, 2013) |
| "Tranexamic acid (TXA) has been shown clinically to reduce mortality in hemorrhaging and head-injured trauma patients and has the potential to mitigate secondary brain injury with its reported antifibrinolytic and antiinflammatory properties." | 5.46 | Impact of tranexamic acid on coagulation and inflammation in murine models of traumatic brain injury and hemorrhage. ( Boudreau, RM; Caldwell, CC; Friend, LA; Goetzman, H; Goodman, MD; Johnson, M; Makley, AT; Pritts, TA; Veile, R, 2017) |
| "The use of tranexamic acid (TXA) is established in the treatment of bleeding, especially of bleeding due to hyperfibrinolysis." | 5.12 | [Tranexamic acid for bleeding prophylaxis in orthopedic surgery and trauma-standard or customized therapy?] ( Möhnle, P; Pekrul, I; Schachtner, T; Zwißler, B, 2021) |
| " There have been many changes in the management of massive hemorrhage, for example, the administration of the tranexamic acid and the use of balanced transfusion ratio." | 4.93 | [Management of bleeding and coagulopathy following major trauma]. ( Etxaniz, A; Pita, E, 2016) |
| "The American Trial Using Tranexamic Acid (TXA) in Thrombocytopenia (A-TREAT, NCT02578901) demonstrated no superiority of TXA over placebo in preventing World Health Organization (WHO) grade 2 or higher bleeding in patients with severe thrombocytopenia requiring supportive platelet transfusion following myeloablative therapy for hematologic disorders." | 4.31 | Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. ( Brown, SP; de Laat, B; El Kassar, N; Gernsheimer, TB; Herren, H; Holle, LA; Ilich, A; Key, NS; Lucas, AT; May, S; Triulzi, DJ; Wolberg, AS, 2023) |
| " Based on current evidence the elements of an evolving strategy in transfusion management and bleeding control are exposed to use of tranexamic acid, combination and ratios of blood products, use of fluids and viscoelastic testing, etc." | 4.12 | Massive transfusion in trauma: an evolving paradigm. ( Bouzat, P; Gauss, T; Moyer, JD, 2022) |
| "Tranexamic acid is a cheap and easy to use drug for the treatment and prevention of bleeding." | 4.02 | [Tranexamic acid: widely applicable, few risks]. ( Meijer, K; Stein-Wit, MA, 2021) |
| " Tranexamic Acid (TXA) is used as an anti-fibrinolytic agent to reduce surgical bleeding if administered prior to or during surgery, and to improve survival in trauma if given early after trauma." | 3.91 | Effect of tranexamic acid administration on acute traumatic coagulopathy in rats with polytrauma and hemorrhage. ( Benov, A; Cap, AP; Darlington, DN; Keesee, JD; Liu, B; Wu, X, 2019) |
| "A high platelet or plasma to RBC ratio, and use of tranexamic acid were associated with a decreased need for massive transfusion and increased survival in injured patients with bleeding." | 3.85 | Combined effect of therapeutic strategies for bleeding injury on early survival, transfusion needs and correction of coagulopathy. ( Baksaas-Aasen, K; Balvers, K; Brohi, K; Eaglestone, S; Gaarder, C; Goslings, JC; Johansson, PI; Juffermans, NP; Maegele, M; Ostrowski, SR; Stanworth, S; Stensballe, J; van Dieren, S, 2017) |
| " Our purposes were to study the efficacy of tranexamic acid (TXA) and prothrombin complex concentrate (PCC) on a traumatic coagulopathy with a severe native metabolic acidosis and compare the efficacy of PCC versus fresh frozen plasma (FFP) to reverse a dilutional coagulopathy." | 3.79 | The effects of tranexamic acid and prothrombin complex concentrate on the coagulopathy of trauma: an in vitro analysis of the impact of severe acidosis. ( Eckert, M; Izenberg, S; Martin, MJ; McVay, D; Nelson, D; Porta, CR; Salgar, S, 2013) |
| "Among adults with major trauma and suspected trauma-induced coagulopathy who were being treated in advanced trauma systems, prehospital administration of tranexamic acid followed by an infusion over 8 hours did not result in a greater number of patients surviving with a favorable functional outcome at 6 months than placebo." | 3.30 | Prehospital Tranexamic Acid for Severe Trauma. ( Bernard, SA; Burns, B; Cameron, PA; Dicker, B; Forbes, AB; Gantner, DC; Gruen, RL; Hurford, S; Maegele, M; Martin, CA; Mazur, SM; McArthur, CJ; Medcalf, RL; Mitra, B; Murray, LJ; Myles, PS; Ng, SJ; Pitt, V; Rashford, S; Reade, MC; Swain, AH; Trapani, T; Young, PJ, 2023) |
| " Pharmacokinetic-pharmacodynamic modelling of these data might identify the best pharmacodynamic monitoring criteria and the optimal tranexamic acid dosing regimen for treatment of postpartum haemorrhage." | 3.11 | Tranexamic acid dose-response relationship for antifibrinolysis in postpartum haemorrhage during Caesarean delivery: TRACES, a double-blind, placebo-controlled, multicentre, dose-ranging biomarker study. ( Allorge, D; Broisin, F; Constant, B; Ducloy-Bouthors, AS; Duhamel, A; Faraoni, D; Favier, R; Ghesquiere, L; Gilliot, S; Gouez, AL; Hennart, B; Jeanpierre, E; Keita-Meyer, H; Kyheng, M; Lebuffe, G; Moyanotidou, G; Odou, P; Peynaud, E; Rigouzzo, A; Susen, S; Turbelin, A, 2022) |
| "Hemorrhage and trauma-induced coagulopathy cause significant morbidity and mortality in trauma patients." | 3.01 | Alternative blood products in trauma. ( Jan, KM; Mohapatra, S; Moon, TS, 2023) |
| "While D-dimer and PAP levels reflect a lower degree of fibrinolysis following prehospital administration of TXA when compared with placebo in a large prehospital trial of patients with TBI, TEG obtained on admission and 6 hours later did not demonstrate any differences in fibrinolysis between the two TXA dosing regimens and placebo." | 2.94 | Tranexamic acid administration in the field does not affect admission thromboelastography after traumatic brain injury. ( Aufderheide, TP; Callum, J; Dewey, E; Dixon, AL; Dries, DJ; Farrell, DH; Frascone, RJ; Gandhi, RR; Garrett, JS; Jui, J; Kannas, D; McCully, BH; McMullan, J; Morrison, LJ; Rick, EA; Robinson, BRH; Rowell, SE; Schreiber, MA; Tallon, JM; Tibbs, B; Wade, CE; Weisfeldt, ML; Williams, C, 2020) |
| "Tranexamic acid (TXA) is a popular antifibrinolytic drug widely used in hemorrhagic trauma patients and cardiovascular, orthopedic, and gynecological surgical patients." | 2.82 | Tranexamic acid: Beyond antifibrinolysis. ( Carter, D; Falank, C; Kacer, D; Kramer, R; Palmeri, M; Prudovsky, I; Rappold, J; Zucco, VV, 2022) |
| "Special trauma populations at particularly high risk are also reviewed, including the geriatric population, as well as unstable pelvic fractures, which are each at increased risk for poor outcomes, and deserve special attention." | 2.66 | Limiting Blood Loss in Orthopaedic Trauma: Strategies and Effects. ( Leighton, JL; Schneider, P; You, D, 2020) |
| "Acute blood loss in trauma requires quick identification and action to restore circulating volume and save the patient." | 2.66 | Massive transfusion protocol in adult trauma population. ( Boneva, D; Elkbuli, A; McKenney, M; Meneses, E, 2020) |
| "The improved understanding of trauma-induced coagulopathy in adults has led to an evolution in the strategies of damage-control resuscitation." | 2.61 | Pediatric trauma-related coagulopathy: Balanced resuscitation, goal-directed therapy and viscoelastic assays. ( Drucker, NA; Newton, C; Wang, SK, 2019) |
| "Uncontrolled hemorrhage and subsequent trauma-induced coagulopathy (TIC) are still the principle causes for preventable death after trauma and early detection and aggressive management have been associated with reduced mortality." | 2.55 | Updated concepts on the pathophysiology and the clinical management of trauma hemorrhage and coagulopathy. ( Gu, ZT; Huang, QB; Maegele, M; Yang, H, 2017) |
| "The use of tranexamic acid in trauma was supported by "high" quality evidence according to the GRADE classification but was downgraded to "moderate" for external validity issues." | 2.53 | Blood Component Therapy and Coagulopathy in Trauma: A Systematic Review of the Literature from the Trauma Update Group. ( Chiara, O; Chieregato, A; Coniglio, C; Cortegiani, A; De Blasio, E; Fossi, F; Gianesello, L; Gordini, G; Grossi, S; Mengoli, F; Orzalesi, V; Pellegrini, C; Poole, D; Russo, E; Volpi, A, 2016) |
| "Paediatric trauma is the leading cause of mortality in children." | 2.53 | Paediatric trauma resuscitation: an update. ( Giannoudis, PV; Tosounidis, TH, 2016) |
| "In most trauma centres, coagulation therapy is established with transfusion of high volumes of fresh frozen plasma." | 2.52 | Management of traumatic haemorrhage--the European perspective. ( Schlimp, CJ; Schöchl, H; Voelckel, W, 2015) |
| "The morbidity and mortality of postpartum hemorrhage (PPH) in women with an underlying bleeding disorder requires vigilance by the hematologist." | 2.52 | An update on the management of bleeding disorders during pregnancy. ( Kouides, PA, 2015) |
| " Additionally, risk of thromboembolism, dosing regimens, and timing of dosing are assessed." | 2.52 | Tranexamic acid: from trauma to routine perioperative use. ( Pittet, JF; Sikorski, RA; Simmons, J, 2015) |
| " The latter testing can be applied to guide the dosing of fibrinogen and prothrombin complex concentrate, which are selectively used to correct fibrinogen deficiency, and improve thrombin generation in acquired coagulopathy." | 2.50 | Novel approaches in management of perioperative coagulopathy. ( Bader, SO; Görlinger, K; Tanaka, KA, 2014) |
| "The coagulopathy induced by trauma is independently associated with mortality, increased transfusion requirements, multiple organ dysfunction, infections, increased intensive care unit (ICU) length of stay, and costs." | 2.50 | A systematic review of antifibrinolytics and massive injury. ( Faraoni, D; Van Der Linden, P, 2014) |
| "Diagnosis and treatment of trauma-induced coagulopathy (TIC) presents a challenge for trauma care providers." | 2.49 | Potential value of pharmacological protocols in trauma. ( Schlimp, CJ; Schöchl, H; Voelckel, W, 2013) |
| "Future treatment of trauma-induced coagulopathy may be based on systemic antifibrinolytics, local haemostatics and individualized point-of-care-guided rational use of coagulation factor concentrates such as fibrinogen, prothrombin complex concentrate, recombinant factor VIIa and factor XIII." | 2.48 | Emerging treatment strategies for trauma-induced coagulopathy. ( Fries, D; Sorensen, B, 2012) |
| "Current evidence in trauma resuscitation indicates a potential role for coagulation factor concentrates and other haemostatic agents in correcting trauma-induced coagulopathy." | 2.48 | Coagulation management. ( Grottke, O, 2012) |
| "Menorrhagia is defined as menstrual periods lasting more than 7 days and/or involving blood loss greater than 80ml." | 2.46 | Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. ( Agostini, A; Bazot, M; Brailly-Tabard, S; Brun, JL; Chabbert-Buffet, N; Cravello, L; De Raucourt, E; Fauconnier, A; Fernandez, H; Gervaise, A; Golfier, F; Gompel, A; Gondry, J; Graesslin, O; Huchon, C; Lucot, JP; Marret, H; Plu-Bureau, G; Roman, H, 2010) |
| "Ligneous conjunctivitis is the most recognizable, well-documented, and common presentation of the clinical syndromes associated with plasminogen deficiency, although numerous other organs have been reported to be affected." | 2.44 | Plasminogen deficiency. ( Mehta, R; Shapiro, AD, 2008) |
| "The results of a test of the total thrombus-formation analysis system showed improved blood clot formation ability." | 1.56 | Effect of Tranexamic Acid for Traumatic Brain Injury: A Case Report. ( Inoue, S; Miike, T; Sakamoto, Y, 2020) |
| "An academic level 1 trauma centre in the Lyon Region, from March 2011 to December 2016." | 1.56 | Fibrinolytic shutdown diagnosed with rotational thromboelastometry represents a moderate form of coagulopathy associated with transfusion requirement and mortality: A retrospective analysis. ( Bouzat, P; David, JS; Geay-Baillat, AM; Inaba, K; Incagnoli, P; Lambert, A; Maegele, M; Taverna, XJ, 2020) |
| "Heavy menstrual bleeding is defined as excessive menstrual blood loss that interferes with a woman's physical, social, emotional, or material quality of life." | 1.51 | Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding: ACOG COMMITTEE OPINION SUMMARY, Number 785. ( , 2019) |
| "Heavy menstrual bleeding is defined as excessive menstrual blood loss that interferes with a woman's physical, social, emotional, or material quality of life." | 1.51 | Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding: ACOG COMMITTEE OPINION, Number 785. ( , 2019) |
| "Among the 518 major trauma patients admitted to the trauma centres during the study period, 235 patients (118 in the pre-ECS period and 117 in the ECS period) matched one of the inclusion criteria and were enrolled in the study." | 1.51 | Early coagulation support protocol: A valid approach in real-life management of major trauma patients. Results from two Italian centres. ( Antonelli, M; Barelli, R; Bianchi, M; Bocci, MG; Caricato, A; Cingolani, E; Cutuli, SL; De Candia, E; De Pascale, G; Dell'Anna, AM; Fiore, V; Grieco, DL; Maresca, M; Mercurio, G; Nardi, G; Palma, A; Rondinelli, MB; Tersali, A; Veronesi, G, 2019) |
| "He was presented in hemorrhagic shock, with an initial lactate of 10." | 1.48 | Hyperfibrinolysis diagnosed with rotational thromboelastometry and treated with tranexamic acid in a dog with acute traumatic coagulopathy. ( Muri, B; Schmierer, P; Schwarz, A; Sigrist, N, 2018) |
| "Tranexamic acid (TXA) has been shown clinically to reduce mortality in hemorrhaging and head-injured trauma patients and has the potential to mitigate secondary brain injury with its reported antifibrinolytic and antiinflammatory properties." | 1.46 | Impact of tranexamic acid on coagulation and inflammation in murine models of traumatic brain injury and hemorrhage. ( Boudreau, RM; Caldwell, CC; Friend, LA; Goetzman, H; Goodman, MD; Johnson, M; Makley, AT; Pritts, TA; Veile, R, 2017) |
| "Fibrinogen level was normalized within two days (2." | 1.43 | Primary hyperfibrinolysis as the presenting sign of prostate cancer: A case report. ( Cvetković, Z; Kulić, A; Libek, V, 2016) |
| "Anaphylaxis during pregnancy is rare but life threatening to both mother and fetus." | 1.42 | Anaphylaxis-induced hyperfibrinolysis in pregnancy. ( Browning, RM; Truong, HT, 2015) |
| "Changes in the hemostasis system in choledocholithiasis, taking into account the obturation jaundice severity and possibility of the correction conduction, using miniinvasive operative interventions, were studied." | 1.40 | [Changes of the hemostasis system in patients with obturation jaundice caused by choledocholithiasis, and possibilities of their correction with the help of miniinvasive operative interventions]. ( Tkachenko, AI, 2014) |
| "The aim of the study was to create a trauma coagulopathy model (TCM) with a hyperfibrinolysis thrombelastography (TEG) pattern similar to injured patients and test the effects of different resuscitation fluids and antifibrinolytics on fibrinolysis." | 1.39 | Influence of resuscitation fluids, fresh frozen plasma and antifibrinolytics on fibrinolysis in a thrombelastography-based, in-vitro, whole-blood model. ( Cotton, BA; Holcomb, JB; Kostousov, V; Matijevic, N; Wade, CE; Wang, YW, 2013) |
| "We present a case of suspected amniotic fluid embolism that presented with sudden respiratory arrest associated with haemodynamic compromise during a non-elective caesarean delivery." | 1.39 | Hyperfibrinolysis diagnosed by rotational thromboelastometry in a case of suspected amniotic fluid embolism. ( Bloor, M; Collins, NF; McDonnell, NJ, 2013) |
| "It is present in 2-8% of trauma patients and associated with shock and increased mortality." | 1.37 | [Hyperfibrinolysis as the cause of haemorrhage and increased mortality in trauma patients]. ( Afshari, A; Johansson, PI; Stensballe, J; Wikkelsø, AJ, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (6.42) | 18.7374 |
| 1990's | 9 (8.26) | 18.2507 |
| 2000's | 8 (7.34) | 29.6817 |
| 2010's | 57 (52.29) | 24.3611 |
| 2020's | 28 (25.69) | 2.80 |
| Authors | Studies |
|---|---|
| Qiao, J | 1 |
| Ray, B | 1 |
| Wians, F | 1 |
| Abadie, J | 1 |
| Gauss, T | 1 |
| Moyer, JD | 1 |
| Bouzat, P | 2 |
| Prudovsky, I | 1 |
| Kacer, D | 1 |
| Zucco, VV | 1 |
| Palmeri, M | 1 |
| Falank, C | 1 |
| Kramer, R | 1 |
| Carter, D | 1 |
| Rappold, J | 1 |
| Ilich, A | 1 |
| Gernsheimer, TB | 1 |
| Triulzi, DJ | 1 |
| Herren, H | 1 |
| Brown, SP | 1 |
| Holle, LA | 1 |
| Lucas, AT | 1 |
| de Laat, B | 1 |
| El Kassar, N | 1 |
| Wolberg, AS | 1 |
| May, S | 1 |
| Key, NS | 2 |
| Borgman, MA | 1 |
| Nishijima, DK | 1 |
| Ducloy-Bouthors, AS | 1 |
| Gilliot, S | 1 |
| Kyheng, M | 1 |
| Faraoni, D | 2 |
| Turbelin, A | 1 |
| Keita-Meyer, H | 1 |
| Rigouzzo, A | 1 |
| Moyanotidou, G | 1 |
| Constant, B | 1 |
| Broisin, F | 1 |
| Gouez, AL | 1 |
| Favier, R | 1 |
| Peynaud, E | 1 |
| Ghesquiere, L | 1 |
| Lebuffe, G | 1 |
| Duhamel, A | 1 |
| Allorge, D | 1 |
| Susen, S | 1 |
| Hennart, B | 1 |
| Jeanpierre, E | 1 |
| Odou, P | 1 |
| Gosselin, AR | 1 |
| White, NJ | 1 |
| Bargoud, CG | 1 |
| Hanna, JS | 1 |
| Tutwiler, V | 1 |
| Jan, KM | 1 |
| Mohapatra, S | 1 |
| Moon, TS | 1 |
| Gruen, RL | 1 |
| Mitra, B | 1 |
| Bernard, SA | 1 |
| McArthur, CJ | 1 |
| Burns, B | 1 |
| Gantner, DC | 1 |
| Maegele, M | 6 |
| Cameron, PA | 1 |
| Dicker, B | 1 |
| Forbes, AB | 1 |
| Hurford, S | 1 |
| Martin, CA | 1 |
| Mazur, SM | 1 |
| Medcalf, RL | 1 |
| Murray, LJ | 1 |
| Myles, PS | 1 |
| Ng, SJ | 1 |
| Pitt, V | 1 |
| Rashford, S | 1 |
| Reade, MC | 1 |
| Swain, AH | 1 |
| Trapani, T | 1 |
| Young, PJ | 1 |
| Moore, HB | 3 |
| Moore, BA | 1 |
| Sauaia, A | 2 |
| Moore, EE | 2 |
| David, JS | 3 |
| Lambert, A | 1 |
| Incagnoli, P | 1 |
| Geay-Baillat, AM | 1 |
| Taverna, XJ | 1 |
| Inaba, K | 2 |
| Wu, X | 1 |
| Benov, A | 1 |
| Darlington, DN | 1 |
| Keesee, JD | 1 |
| Liu, B | 1 |
| Cap, AP | 2 |
| Bocci, MG | 1 |
| Nardi, G | 2 |
| Veronesi, G | 1 |
| Rondinelli, MB | 1 |
| Palma, A | 1 |
| Fiore, V | 1 |
| De Candia, E | 1 |
| Bianchi, M | 1 |
| Maresca, M | 1 |
| Barelli, R | 1 |
| Tersali, A | 1 |
| Dell'Anna, AM | 1 |
| De Pascale, G | 1 |
| Cutuli, SL | 1 |
| Mercurio, G | 1 |
| Caricato, A | 1 |
| Grieco, DL | 1 |
| Antonelli, M | 1 |
| Cingolani, E | 1 |
| Miike, T | 1 |
| Sakamoto, Y | 1 |
| Inoue, S | 1 |
| Wu, TB | 1 |
| Orfeo, T | 1 |
| Sumislawski, JJ | 1 |
| Cohen, MJ | 1 |
| Petzold, LR | 1 |
| Leighton, JL | 1 |
| You, D | 1 |
| Schneider, P | 1 |
| Fletcher-Sandersjöö, A | 1 |
| Thelin, EP | 1 |
| Svensson, M | 1 |
| Bellander, BM | 1 |
| Kinsey, KE | 1 |
| Ganz, E | 1 |
| Khalil, S | 1 |
| Brustman, L | 1 |
| Hanley, C | 1 |
| Callum, J | 2 |
| Jerath, A | 1 |
| Meneses, E | 1 |
| Boneva, D | 1 |
| McKenney, M | 1 |
| Elkbuli, A | 1 |
| Dixon, AL | 1 |
| McCully, BH | 1 |
| Rick, EA | 1 |
| Dewey, E | 1 |
| Farrell, DH | 2 |
| Morrison, LJ | 1 |
| McMullan, J | 1 |
| Robinson, BRH | 1 |
| Tibbs, B | 1 |
| Dries, DJ | 1 |
| Jui, J | 1 |
| Gandhi, RR | 1 |
| Garrett, JS | 1 |
| Weisfeldt, ML | 1 |
| Wade, CE | 2 |
| Aufderheide, TP | 1 |
| Frascone, RJ | 1 |
| Tallon, JM | 1 |
| Kannas, D | 1 |
| Williams, C | 1 |
| Rowell, SE | 2 |
| Schreiber, MA | 1 |
| Hayward, CPM | 1 |
| Tasneem, S | 1 |
| Rivard, GE | 1 |
| Barrett, CD | 1 |
| Vigneshwar, N | 1 |
| Dhara, S | 1 |
| Chandler, J | 1 |
| Chapman, MP | 1 |
| Yaffe, MB | 1 |
| Černý, V | 1 |
| Agostini, V | 1 |
| Fries, D | 3 |
| Leal-Noval, SR | 1 |
| Nardai, G | 1 |
| Östlund, A | 1 |
| Schöchl, H | 4 |
| Pekrul, I | 1 |
| Schachtner, T | 1 |
| Zwißler, B | 1 |
| Möhnle, P | 1 |
| Stein-Wit, MA | 1 |
| Meijer, K | 1 |
| Langhorn, R | 1 |
| Poulsen, MK | 1 |
| Heidemann, PL | 1 |
| Bochsen, L | 1 |
| Ritz, C | 1 |
| Kristensen, AT | 1 |
| Nielsen, LN | 1 |
| Anderson, TN | 1 |
| Duque, P | 1 |
| Gonzalez-Zarco, L | 1 |
| Martínez, R | 1 |
| Gago, S | 1 |
| Varela, JA | 1 |
| Pabinger, I | 1 |
| Streif, W | 1 |
| Toller, W | 1 |
| Gu, ZT | 1 |
| Huang, QB | 1 |
| Yang, H | 1 |
| Boudreau, RM | 1 |
| Johnson, M | 1 |
| Veile, R | 1 |
| Friend, LA | 1 |
| Goetzman, H | 1 |
| Pritts, TA | 1 |
| Caldwell, CC | 1 |
| Makley, AT | 1 |
| Goodman, MD | 1 |
| Levy, JH | 2 |
| Koster, A | 1 |
| Quinones, QJ | 1 |
| Milling, TJ | 1 |
| Meizoso, JP | 1 |
| Dudaryk, R | 1 |
| Mulder, MB | 1 |
| Ray, JJ | 1 |
| Karcutskie, CA | 1 |
| Eidelson, SA | 1 |
| Namias, N | 1 |
| Schulman, CI | 1 |
| Proctor, KG | 1 |
| Kulić, A | 1 |
| Cvetković, Z | 1 |
| Libek, V | 1 |
| Muri, B | 1 |
| Schmierer, P | 1 |
| Schwarz, A | 1 |
| Sigrist, N | 1 |
| Kuckelman, J | 1 |
| Barron, M | 1 |
| Moe, D | 1 |
| Lallemand, M | 1 |
| McClellan, J | 1 |
| Marko, S | 1 |
| Eckert, M | 2 |
| Martin, MJ | 2 |
| Chico Fernández, M | 1 |
| Mudarra Reche, C | 1 |
| Roter, E | 1 |
| Bertolizio, G | 1 |
| Collard, V | 1 |
| Paquet, C | 1 |
| Ingelmo, P | 1 |
| Zhang, YM | 1 |
| Yang, B | 1 |
| Sun, XD | 1 |
| Zhang, Z | 1 |
| Drucker, NA | 1 |
| Wang, SK | 1 |
| Newton, C | 1 |
| Pluta, J | 1 |
| Cieniewicz, A | 1 |
| Trzebicki, J | 1 |
| Vulliamy, P | 1 |
| Thaventhiran, AJ | 1 |
| Davenport, RA | 1 |
| Kostousov, V | 1 |
| Wang, YW | 1 |
| Cotton, BA | 1 |
| Holcomb, JB | 2 |
| Matijevic, N | 1 |
| Godier, A | 1 |
| Dargaud, Y | 1 |
| Prat, N | 1 |
| Pidcoke, HF | 1 |
| Sailliol, A | 1 |
| Porta, CR | 1 |
| Nelson, D | 1 |
| McVay, D | 1 |
| Salgar, S | 1 |
| Izenberg, S | 1 |
| Tanaka, KA | 1 |
| Bader, SO | 1 |
| Görlinger, K | 2 |
| Van Der Linden, P | 1 |
| Pham, HP | 1 |
| Shaz, BH | 1 |
| Theusinger, OM | 1 |
| Stein, P | 1 |
| Spahn, DR | 1 |
| Franchini, M | 1 |
| Mannucci, PM | 3 |
| Tkachenko, AI | 1 |
| Ray, S | 2 |
| Ray, A | 2 |
| Voelckel, W | 2 |
| Schlimp, CJ | 2 |
| Simmons, J | 1 |
| Sikorski, RA | 1 |
| Pittet, JF | 1 |
| Truong, HT | 1 |
| Browning, RM | 1 |
| Kouides, PA | 1 |
| Etxaniz, A | 1 |
| Pita, E | 1 |
| Panteli, M | 1 |
| Pountos, I | 1 |
| Giannoudis, PV | 2 |
| Tosounidis, TH | 1 |
| Abuelkasem, E | 1 |
| Lu, S | 1 |
| Tanaka, K | 1 |
| Planinsic, R | 1 |
| Sakai, T | 1 |
| Collins, P | 1 |
| Abdul-Kadir, R | 1 |
| Thachil, J | 1 |
| Daniel, Y | 1 |
| Habas, S | 1 |
| Malan, L | 1 |
| Escarment, J | 1 |
| Peyrefitte, S | 1 |
| Poole, D | 1 |
| Cortegiani, A | 1 |
| Chieregato, A | 1 |
| Russo, E | 1 |
| Pellegrini, C | 1 |
| De Blasio, E | 1 |
| Mengoli, F | 1 |
| Volpi, A | 1 |
| Grossi, S | 1 |
| Gianesello, L | 1 |
| Orzalesi, V | 1 |
| Fossi, F | 1 |
| Chiara, O | 1 |
| Coniglio, C | 1 |
| Gordini, G | 1 |
| Wong, H | 1 |
| Curry, N | 1 |
| Stanworth, SJ | 1 |
| Stensballe, J | 3 |
| Johansson, PI | 3 |
| Steinmetz, J | 1 |
| Balvers, K | 1 |
| van Dieren, S | 1 |
| Baksaas-Aasen, K | 1 |
| Gaarder, C | 1 |
| Brohi, K | 1 |
| Eaglestone, S | 1 |
| Stanworth, S | 1 |
| Ostrowski, SR | 1 |
| Goslings, JC | 1 |
| Juffermans, NP | 1 |
| Kopp, R | 1 |
| Bruells, C | 1 |
| Mehta, R | 1 |
| Shapiro, AD | 1 |
| Jansen, JO | 1 |
| Thomas, R | 1 |
| Loudon, MA | 1 |
| Brooks, A | 1 |
| Marret, H | 1 |
| Fauconnier, A | 1 |
| Chabbert-Buffet, N | 1 |
| Cravello, L | 1 |
| Golfier, F | 1 |
| Gondry, J | 1 |
| Agostini, A | 1 |
| Bazot, M | 1 |
| Brailly-Tabard, S | 1 |
| Brun, JL | 1 |
| De Raucourt, E | 1 |
| Gervaise, A | 1 |
| Gompel, A | 1 |
| Graesslin, O | 1 |
| Huchon, C | 1 |
| Lucot, JP | 1 |
| Plu-Bureau, G | 1 |
| Roman, H | 1 |
| Fernandez, H | 1 |
| Wikkelsø, AJ | 1 |
| Afshari, A | 1 |
| Sniecinski, RM | 1 |
| Weightman, WM | 1 |
| Gibbs, NM | 1 |
| Beynon, C | 1 |
| Hoffmann, T | 1 |
| Wick, W | 1 |
| Unterberg, AW | 1 |
| Kiening, KL | 1 |
| Sorensen, B | 1 |
| Boling, B | 1 |
| Moore, K | 1 |
| Grottke, O | 1 |
| Collins, NF | 1 |
| Bloor, M | 1 |
| McDonnell, NJ | 1 |
| Dirkmann, D | 1 |
| Radü-Berlemann, J | 1 |
| Peters, J | 1 |
| Gumbert, S | 1 |
| Koh, MB | 1 |
| Hunt, BJ | 1 |
| Tobias, JD | 1 |
| Szekely, E | 1 |
| Baralle, MM | 1 |
| Raoul, G | 1 |
| Marey, A | 1 |
| Ferri, J | 1 |
| Rada, RE | 1 |
| Sarris, I | 1 |
| Arafa, A | 1 |
| Konaris, L | 1 |
| Kadir, RA | 1 |
| Trotter, MI | 1 |
| De, R | 1 |
| Drake-Lee, A | 1 |
| Sabato, AF | 1 |
| Foti, A | 1 |
| De Cosmo, G | 1 |
| Bondoli, A | 1 |
| Wegener, T | 1 |
| Wegenius, G | 1 |
| Saldeen, T | 1 |
| Erikson, U | 1 |
| Rousou, JA | 1 |
| Engelman, RM | 1 |
| Flack, JE | 1 |
| Deaton, DW | 1 |
| Owen, SG | 1 |
| Kang, Y | 1 |
| Prinsley, P | 1 |
| Wood, M | 1 |
| Lee, CA | 1 |
| Bernardoni-Socorro, C | 1 |
| Arteaga-Vizcaino, M | 1 |
| Villamizar, Y | 1 |
| Diez-Ewald, M | 1 |
| Vizcaíno-Salazar, G | 1 |
| Torres-Guerra, E | 1 |
| Quintero, J | 1 |
| Hill, A | 1 |
| Cattaneo, M | 1 |
| Prentice, CR | 1 |
| Valsecchi, A | 1 |
| Cappelletti, M | 1 |
| Eikenboom, JC | 1 |
| van der Meer, FJ | 1 |
| Briët, E | 1 |
| Street, AM | 1 |
| Leung, W | 1 |
| Ramström, G | 1 |
| Blombäck, M | 1 |
| Egberg, N | 1 |
| Johnsson, H | 1 |
| Ljungberg, B | 1 |
| Schulman, S | 1 |
| Bell, AJ | 1 |
| Chisholm, M | 1 |
| Hickton, M | 1 |
| Kettle, P | 1 |
| Mayne, EE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Tranexamic Acid to Reduce Blood Loss in Hemorrhagic Caesarean Delivery: a Multicenter Randomized Double Blind Placebo Controlled Therapeutic and Pharmaco-biological Dose Ranging Study (TRACES) for Its Optimal Benefit/Risk[NCT02797119] | Phase 4 | 225 participants (Actual) | Interventional | 2016-03-15 | Terminated (stopped due to Study will be stopped due to the impossibility of reaching the objective of inclusions within a reasonable time frame and taking into account the recommendations of the international WOMAN study) | ||
| The Efficacy and Safety of Intrauterine Misoprostol Versus Intravenous Tranexamic Acid in Reducing Blood Loss During and After Cesarean Delivery in Patients With Placenta Previa: A Randomized Controlled Trial[NCT05340205] | Phase 4 | 81 participants (Actual) | Interventional | 2022-05-04 | Completed | ||
| Management of Perioperative Coagulopathy With Thromboelastometry (ROTEM) in Liver Transplant[NCT02239991] | 100 participants (Anticipated) | Interventional | 2014-09-30 | Recruiting | |||
| Recombinant Activated Factor VII (rFVIIa/ NovoSeven®) in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia[NCT03251547] | 76 participants (Actual) | Observational | 2017-08-21 | Completed | |||
| Management of Recurrent and Progressive Ligneous Conjunctivitis Due to Plasminogen Deficiency. An N of One Clinical Trial of Topical Administration of Allogenic Plasma to Affected Eye[NCT05404932] | 1 participants (Anticipated) | Interventional | 2022-12-15 | Recruiting | |||
| Estimation of Coagulation Factor XIII Activity Based on the Initial Plasma Fibrinogen Level in Trauma[NCT03634215] | 357 participants (Actual) | Observational | 2018-09-01 | Completed | |||
| A Prospective, Randomized, Single-blinded, Non-inferiority Study to Evaluate the Safety and Efficacy of the Saline-coupled Bipolar Sealer Compared to the Unipolar Electrocautery in Primary Unilateral Total Knee Arthroplasty[NCT03952546] | 211 participants (Actual) | Interventional | 2019-05-07 | Completed | |||
| Peri-articular Tranexamic Acid Injection in Total Knee Arthroplasty: A Randomized Controlled Trial[NCT02829346] | Phase 2 | 60 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Functional outcomes measured by the 2011 Knee Society Score. The Functional Activities section consists of 4 sub-sections with a total score ranging from 0-100 points. The higher the numerical value the better the outcome. The sub-sections consist of: (1)Walking and Standing 0-30 points (2)Standard Activities 0-30 points (3)Advanced Activities 0-25 points (4)Discretionary Knee Activities 0-15 points." (NCT03952546)
Timeframe: 8 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Treatment Arm | 56.45 |
| Control Arm | 61.79 |
Postoperative day 1 estimated blood loss as calculated by the Gross' Formula (NCT03952546)
Timeframe: Postoperative day 1
| Intervention | milliliters (Mean) |
|---|---|
| Treatment Arm | 924 |
| Control Arm | 1062 |
Participants were assessed for any wound infection within 90 days of surgery. (NCT03952546)
Timeframe: 90 days postoperatively
| Intervention | Number of events (Number) |
|---|---|
| Saline-Coupled Bipolar Sealer | 1 |
| Unipolar Electrocautery | 3 |
50 reviews available for tranexamic acid and Coagulation Disorders, Blood
| Article | Year |
|---|---|
Transfusion management of trauma from the 2019 El Paso mass shooting incident.
Topics: Blood Coagulation Disorders; Blood Transfusion; Humans; Plasma; Retrospective Studies; Thrombelastog | 2022 |
Tranexamic acid: Beyond antifibrinolysis.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Fibrinolysin; Fibrinolysis; Hemorrhage; Humans | 2022 |
Alternative blood products in trauma.
Topics: Blood Coagulation Disorders; Fibrinogen; Hemorrhage; Hemostatics; Humans; Thrombelastography; Tranex | 2023 |
Limiting Blood Loss in Orthopaedic Trauma: Strategies and Effects.
Topics: Blood Coagulation Disorders; Hemostasis; Humans; Orthopedic Procedures; Resuscitation; Shock, Hemorr | 2020 |
Time Course of Hemostatic Disruptions After Traumatic Brain Injury: A Systematic Review of the Literature.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Brain Injuries, Traumatic; Hemostatics; Humans | 2021 |
Massive transfusion protocol in adult trauma population.
Topics: Adult; Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Coagulation Factors; Blood Compon | 2020 |
Variations and obstacles in the use of coagulation factor concentrates for major trauma bleeding across Europe: outcomes from a European expert meeting.
Topics: Blood Coagulation Disorders; Blood Coagulation Factors; Fibrinogen; Hemorrhage; Hemostatics; Humans; | 2022 |
[Tranexamic acid for bleeding prophylaxis in orthopedic surgery and trauma-standard or customized therapy?]
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Loss, Surgical; Hemorrhage; Humans; Orth | 2021 |
Fibrinolysis in Traumatic Brain Injury: Diagnosis, Management, and Clinical Considerations.
Topics: Blood Coagulation; Blood Coagulation Disorders; Brain Injuries, Traumatic; Fibrinolysis; Humans; Tra | 2021 |
Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Blood Coagulation; Blood Coagulation Disorders; Dose-Response Relationship, | 2017 |
Updated concepts on the pathophysiology and the clinical management of trauma hemorrhage and coagulopathy.
Topics: Blood Coagulation Disorders; Blood Transfusion; Hemorrhage; Humans; Practice Guidelines as Topic; Re | 2017 |
Antifibrinolytic Therapy and Perioperative Considerations.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Loss, Surgical; Fibrinolysis; Humans; Pe | 2018 |
Pediatric trauma-related coagulopathy: Balanced resuscitation, goal-directed therapy and viscoelastic assays.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Coagulation Tests; Blood Transfusion; Ch | 2019 |
What's new for trauma haemorrhage management?
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Transfusion; Hemorrhage; Hemostatic Tech | 2019 |
[Evolution of US military transfusion support for resuscitation of trauma and hemorrhagic shock].
Topics: Blood Coagulation Disorders; Blood Component Transfusion; Blood Transfusion; Forecasting; Hemostatic | 2013 |
Novel approaches in management of perioperative coagulopathy.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Elasticity; Fibrinogen; Hemostasis; Humans; Pe | 2014 |
A systematic review of antifibrinolytics and massive injury.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Hemorrhage; Humans; Tranexamic Acid; Wounds an | 2014 |
Update on massive transfusion.
Topics: Blood Coagulation Disorders; Blood Coagulation Factors; Blood Transfusion; Hemorrhage; Humans; Throm | 2013 |
Applying 'Patient Blood Management' in the trauma center.
Topics: Anemia; Blood Coagulation Disorders; Blood Coagulation Factors; Blood Transfusion; Deamino Arginine | 2014 |
Adjunct agents for bleeding.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Clinical Trials as Topic; Hemorrhage; Humans; | 2014 |
Non-surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disorders.
Topics: Adult; Blood Coagulation Disorders; Deamino Arginine Vasopressin; Female; Hemostatics; Humans; Menor | 2014 |
Management of traumatic haemorrhage--the European perspective.
Topics: Blood Coagulation Disorders; Europe; Hemorrhage; Humans; Platelet Transfusion; Thrombin; Tranexamic | 2015 |
Tranexamic acid: from trauma to routine perioperative use.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Hemostasis; Humans; Perioperative Care; Tranex | 2015 |
An update on the management of bleeding disorders during pregnancy.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Coagulation Factors; Female; Hemorrhagic | 2015 |
[Management of bleeding and coagulopathy following major trauma].
Topics: Blood Coagulation Disorders; Hemorrhage; Humans; Multiple Trauma; Tranexamic Acid; Transfusion React | 2016 |
Pharmacological adjuncts to stop bleeding: options and effectiveness.
Topics: Acidosis; Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Coagulation Tests; Blood Trans | 2016 |
Paediatric trauma resuscitation: an update.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Transfusion; Child; Clinical Protocols; | 2016 |
Tactical damage control resuscitation in austere military environments.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Coagulation Factors; Blood Component Tra | 2016 |
Blood Component Therapy and Coagulopathy in Trauma: A Systematic Review of the Literature from the Trauma Update Group.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Component Transfusion; Humans; Mortality | 2016 |
Blood products and procoagulants in traumatic bleeding: use and evidence.
Topics: Blood Coagulation Disorders; Hemorrhage; Hemostasis; Humans; Plasma; Randomized Controlled Trials as | 2016 |
Non-surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disorders.
Topics: Adult; Blood Coagulation Disorders; Deamino Arginine Vasopressin; Female; Hemostatics; Humans; Menor | 2016 |
[Haemostatic resuscitation in bleeding trauma patients].
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Transfusion; Critical Illness; Fluid The | 2016 |
Plasminogen deficiency.
Topics: Adolescent; Adult; Animals; Blood Coagulation Disorders; Child; Child, Preschool; Conjunctivitis; Fe | 2008 |
Damage control resuscitation for patients with major trauma.
Topics: Acidosis; Blood Cells; Blood Coagulation Disorders; Calcium; Factor VIIa; Fibrinogen; Hemostasis; Hu | 2009 |
Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause.
Topics: Adolescent; Adult; Anemia, Iron-Deficiency; Blood Coagulation Disorders; Contraceptives, Oral, Combi | 2010 |
Bleeding and management of coagulopathy.
Topics: Algorithms; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Disorders; Bloo | 2011 |
Management of coagulation: an Australian perspective.
Topics: Australia; Blood Coagulation Disorders; Factor VIIa; Hemorrhage; Humans; Perioperative Care; Platele | 2012 |
Emerging treatment strategies for trauma-induced coagulopathy.
Topics: Acidosis; Anemia; Antifibrinolytic Agents; Bandages; Blood Coagulation Disorders; Blood Coagulation | 2012 |
Tranexamic acid (TXA) use in trauma.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Brain Injuries; Cause of Death; Emergency Serv | 2012 |
Coagulation management.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Coagulation Factors; Evidence-Based Medi | 2012 |
Potential value of pharmacological protocols in trauma.
Topics: Blood Coagulation Disorders; Blood Transfusion; Cardiac Surgical Procedures; Fibrinogen; Hemostatics | 2013 |
Potential value of protocols in substantially bleeding trauma patients.
Topics: Blood Coagulation Disorders; Blood Coagulation Tests; Clinical Protocols; Hemorrhage; Humans; Thromb | 2013 |
The management of perioperative bleeding.
Topics: Aprotinin; Blood Coagulation Disorders; Blood Loss, Surgical; Deamino Arginine Vasopressin; Factor V | 2003 |
Strategies for minimizing blood loss in orthopedic surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Disorders; Blood Loss, Surg | 2004 |
Evidence-based management of epistaxis in adults.
Topics: Administration, Topical; Adult; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Antifibri | 2006 |
Clinical use of synthetic antifibrinolytic agents during liver transplantation.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Loss, Surgical; Clini | 1993 |
Hemostatic drugs.
Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Disorders; Blood Loss, Surgica | 1998 |
Intraventricular hemorrhage: emphasis on prevention.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agents; Blood Coagulation Disorders; Cereb | 1998 |
Current status of non-transfusional haemostatic agents.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Disorders; Blood Loss, Surg | 1999 |
Indications for antifibrinolytic therapy.
Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Disorders; Disseminated Intrav | 1975 |
6 trials available for tranexamic acid and Coagulation Disorders, Blood
| Article | Year |
|---|---|
Tranexamic acid in pediatric hemorrhagic trauma.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Hemorrhage; Humans; Prospective Studies; Retro | 2023 |
Tranexamic acid dose-response relationship for antifibrinolysis in postpartum haemorrhage during Caesarean delivery: TRACES, a double-blind, placebo-controlled, multicentre, dose-ranging biomarker study.
Topics: Antifibrinolytic Agents; Biomarkers; Blood Coagulation Disorders; Cesarean Section; Double-Blind Met | 2022 |
Prehospital Tranexamic Acid for Severe Trauma.
Topics: Adult; Antifibrinolytic Agents; Australia; Blood Coagulation Disorders; Emergency Medical Services; | 2023 |
Tranexamic acid administration in the field does not affect admission thromboelastography after traumatic brain injury.
Topics: Abbreviated Injury Scale; Adolescent; Adult; alpha-2-Antiplasmin; Antifibrinolytic Agents; Blood Coa | 2020 |
Combined intravenous and intra-articular tranexamic acid administration in total knee arthroplasty for preventing blood loss and hyperfibrinolysis: A randomized controlled trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, | 2019 |
Tranexamic acid significantly reduces blood loss associated with coronary revascularization.
Topics: Aged; Blood Coagulation Disorders; Blood Loss, Surgical; Cardiopulmonary Bypass; Erythrocyte Transfu | 1995 |
53 other studies available for tranexamic acid and Coagulation Disorders, Blood
| Article | Year |
|---|---|
Massive transfusion in trauma: an evolving paradigm.
Topics: Blood Coagulation Disorders; Blood Transfusion; Hemorrhage; Humans; Tranexamic Acid; Wounds and Inju | 2022 |
Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Fibrinolysin; Fibrinolysis; Hemorrhage; Humans | 2023 |
Hyperfibrinolysis drives mechanical instabilities in a simulated model of trauma induced coagulopathy.
Topics: Blood Coagulation Disorders; Fibrin; Fibrinogen; Hemodilution; Hemostatics; Humans; Thrombophilia; T | 2022 |
Ilich A, Gernsheimer TB, Triulzi DJ, et al. Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. Blood Adv. 2023;7(6):900-908.
Topics: Blood Coagulation Disorders; Humans; Thrombocytopenia; Tranexamic Acid | 2023 |
Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding: ACOG COMMITTEE OPINION SUMMARY, Number 785.
Topics: Adolescent; Antifibrinolytic Agents; Blood Coagulation Disorders; Contraceptive Agents; Contraceptiv | 2019 |
Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding: ACOG COMMITTEE OPINION, Number 785.
Topics: Adolescent; Antifibrinolytic Agents; Blood Coagulation Disorders; Contraceptive Agents; Contraceptiv | 2019 |
Clinical relevance and practical assessment of fibrinolysis shutdown.
Topics: alpha-2-Antiplasmin; Antifibrinolytic Agents; Blood Coagulation Disorders; Fibrin Fibrinogen Degrada | 2020 |
Fibrinolytic shutdown diagnosed with rotational thromboelastometry represents a moderate form of coagulopathy associated with transfusion requirement and mortality: A retrospective analysis.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Fibrinolysis; Humans; Retrospective Studies; T | 2020 |
Effect of tranexamic acid administration on acute traumatic coagulopathy in rats with polytrauma and hemorrhage.
Topics: Animals; Antifibrinolytic Agents; Biomarkers; Blood Coagulation; Blood Coagulation Disorders; Diseas | 2019 |
Early coagulation support protocol: A valid approach in real-life management of major trauma patients. Results from two Italian centres.
Topics: Adult; Aged; Blood Coagulation; Blood Coagulation Disorders; Blood Transfusion; Clinical Protocols; | 2019 |
Effect of Tranexamic Acid for Traumatic Brain Injury: A Case Report.
Topics: Aged, 80 and over; Antifibrinolytic Agents; Blood Coagulation; Blood Coagulation Disorders; Brain In | 2020 |
Computational model of tranexamic acid on urokinase mediated fibrinolysis.
Topics: alpha 1-Antitrypsin; Antifibrinolytic Agents; Blood Coagulation; Blood Coagulation Disorders; Comput | 2020 |
Intraoperative coagulopathy during cesarean section as an unsuspected initial presentation of COVID-19: a case report.
Topics: Adult; Antifibrinolytic Agents; Betacoronavirus; Blood Coagulation Disorders; Blood Loss, Surgical; | 2020 |
Tranexamic acid and trauma coagulopathy: where are we now?
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Hemorrhage; Humans; Tranexamic Acid; Wounds an | 2021 |
Improved platelet counts during prolonged tranexamic therapy for Quebec platelet disorder implicate the underlying fibrinolytic defect as the cause of lower platelet counts.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Platelets; Factor V Deficiency; Fibrinol | 2020 |
Plasmin thrombelastography rapidly identifies trauma patients at risk for massive transfusion, mortality, and hyperfibrinolysis: A diagnostic tool to resolve an international debate on tranexamic acid?
Topics: Adult; Antifibrinolytic Agents; Biomarkers; Blood Coagulation Disorders; Blood Transfusion; Female; | 2020 |
[Tranexamic acid: widely applicable, few risks].
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Female; Hemorrhage; Hemostatic Techniques; Hum | 2021 |
Diagnosis of primary hyperfibrinolysis and in vitro investigation of the inhibitory effects of tranexamic acid in a group of dogs with sarcomas - A pilot study.
Topics: Animals; Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Coagulation Tests; Case-Control | 2021 |
Tranexamic acid use in severely injured patients, is it always appropriate?
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Fibrinolysis; Hemorrhage; Humans; Tranexamic A | 2021 |
Impact of tranexamic acid on coagulation and inflammation in murine models of traumatic brain injury and hemorrhage.
Topics: Animals; Anti-Inflammatory Agents; Antifibrinolytic Agents; Biomarkers; Blood Coagulation Disorders; | 2017 |
Increased risk of fibrinolysis shutdown among severely injured trauma patients receiving tranexamic acid.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Dose-Response Relationship, Drug; Female; Fibr | 2018 |
Primary hyperfibrinolysis as the presenting sign of prostate cancer: A case report.
Topics: Adenocarcinoma; Antifibrinolytic Agents; Biomarkers; Blood Coagulation Disorders; Blood Coagulation | 2016 |
Hyperfibrinolysis diagnosed with rotational thromboelastometry and treated with tranexamic acid in a dog with acute traumatic coagulopathy.
Topics: Accidents, Traffic; Animals; Antifibrinolytic Agents; Blood Coagulation Disorders; Dog Diseases; Dog | 2018 |
Plasma coadministration improves resuscitation with tranexamic acid or prothrombin complex in a porcine hemorrhagic shock model.
Topics: Animals; Blood Coagulation Disorders; Blood Coagulation Factors; Blood Coagulation Tests; Combined M | 2018 |
Traumatic coagulopathies.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Fibrinolysis; Forecasting; Humans; Resuscitati | 2019 |
Use of Tranexamic Acid in an Uncommon Triad: Hemorrhagic Stroke, Sickle Cell Disease and Severe Coagulopathy.
Topics: Anemia, Sickle Cell; Blood Coagulation Disorders; Child; Female; Humans; Intracranial Hemorrhages; M | 2019 |
Response to the article "Perioperative standards for the treatment of coagulation disorders and usage of blood products in patients undergoing liver transplantation used in the Clinic for Transplant Surgery in Wrocław".
Topics: Blood Coagulation Disorders; Blood Transfusion; Hemostasis; Humans; Liver Transplantation; Thrombela | 2019 |
Influence of resuscitation fluids, fresh frozen plasma and antifibrinolytics on fibrinolysis in a thrombelastography-based, in-vitro, whole-blood model.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Coagulation Disorders; Colloids; Crystalloid Solut | 2013 |
Case scenario: management of trauma-induced coagulopathy in a severe blunt trauma patient.
Topics: Accidents, Traffic; Adult; Anticoagulants; Antifibrinolytic Agents; Blood Coagulation Disorders; Ear | 2013 |
The effects of tranexamic acid and prothrombin complex concentrate on the coagulopathy of trauma: an in vitro analysis of the impact of severe acidosis.
Topics: Acidosis; Animals; Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Coagulation Factors; | 2013 |
[Changes of the hemostasis system in patients with obturation jaundice caused by choledocholithiasis, and possibilities of their correction with the help of miniinvasive operative interventions].
Topics: Anticoagulants; Antifibrinolytic Agents; Blood Coagulation Disorders; Choledocholithiasis; Drug Admi | 2014 |
Anaphylaxis-induced hyperfibrinolysis in pregnancy.
Topics: Adult; Anaphylaxis; Antifibrinolytic Agents; Blood Coagulation Disorders; Bronchial Spasm; Crystallo | 2015 |
Comparison between thrombelastography and thromboelastometry in hyperfibrinolysis detection during adult liver transplantation.
Topics: Anesthesia, General; Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Coagulation Tests; | 2016 |
Management of coagulopathy associated with postpartum hemorrhage: guidance from the SSC of the ISTH.
Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Disorders; Blood Transfusion; Cardiology; Facto | 2016 |
Combined effect of therapeutic strategies for bleeding injury on early survival, transfusion needs and correction of coagulopathy.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Transfus | 2017 |
Management of coagulopathy in the severely burned patient: a place for antifibrinolytic therapy?
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Transfusion; Burns; Humans; Tranexamic A | 2017 |
[Hyperfibrinolysis as the cause of haemorrhage and increased mortality in trauma patients].
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Transfusion; Fibrinolysis; Hemorrhage; H | 2011 |
Stereotactic brainstem biopsy in a patient with coagulopathy of unclear etiology: case report.
Topics: Adult; Antifibrinolytic Agents; Astrocytoma; Biopsy; Bleeding Time; Blood Coagulation Disorders; Bra | 2011 |
Hyperfibrinolysis diagnosed by rotational thromboelastometry in a case of suspected amniotic fluid embolism.
Topics: Adult; Antifibrinolytic Agents; Blood Coagulation; Blood Coagulation Disorders; Cesarean Section; Di | 2013 |
Recombinant tissue-type plasminogen activator-evoked hyperfibrinolysis is enhanced by acidosis and inhibited by hypothermia but still can be blocked by tranexamic acid.
Topics: Acidosis; Adult; Blood Coagulation; Blood Coagulation Disorders; Female; Fibrinolytic Agents; Humans | 2013 |
[Dental avulsions and blood coagulation disorders].
Topics: Anticoagulants; Antifibrinolytic Agents; Blood Coagulation Disorders; Deamino Arginine Vasopressin; | 2005 |
Management of the dental patient on anticoagulant medication.
Topics: Anticoagulants; Bleeding Time; Blood Coagulation Disorders; Blood Loss, Surgical; Dental Care for Ch | 2006 |
Topical use of tranexamic acid to control perioperative local bleeding in gynaecology patients with clotting disorders: two cases.
Topics: Administration, Oral; Administration, Topical; Aged; Antifibrinolytic Agents; Blood Coagulation Diso | 2007 |
[Coagulative changes in gynecologic surgery. Clinical and therapeutic evaluation].
Topics: Adult; Aged; Anesthesia; Aprotinin; Blood Coagulation Disorders; Disseminated Intravascular Coagulat | 1980 |
Serial pulmonary angiography in rats with pulmonary damage due to intravascular coagulation.
Topics: Angiography; Animals; Blood Coagulation Disorders; Capillaries; Injections, Intraperitoneal; Lung; L | 1983 |
Adenotonsillectomy in patients with inherited bleeding disorders.
Topics: Adenoidectomy; Blood Coagulation Disorders; Child; Child, Preschool; Deamino Arginine Vasopressin; F | 1993 |
[Mouth-washing with tranexamic acid in patients treated with oral anticoagulants subjected to oral surgery procedures].
Topics: Anticoagulants; Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Loss, Surgical; Dental S | 1998 |
[Possibilities of the use of an inhibitor of hemolysis (AMCHA), by rectal and vaginal administration, for gynecological hemorrhages].
Topics: Adolescent; Adult; Aged; Blood Coagulation Disorders; Child; Cyclohexanecarboxylic Acids; Female; He | 1975 |
Acquired von Willebrand's disease due to excessive fibrinolysis.
Topics: Blood Coagulation Disorders; Fibrinolysis; Hemorrhagic Disorders; Humans; Male; Middle Aged; Tranexa | 1992 |
Use of tranexamic acid mouthwash in dental procedures in patients taking oral anticoagulants.
Topics: Blood Coagulation Disorders; Humans; Surgery, Oral; Tranexamic Acid | 1990 |
Oral surgery in patients with hereditary bleeding disorders. A survey of treatment in the Stockholm area (1974-1985).
Topics: Blood Coagulation Disorders; Blood Coagulation Factors; Clinical Protocols; Dental Care for Disabled | 1989 |
Reversal of coagulopathy in Kasabach-Merritt syndrome with tranexamic acid.
Topics: Afibrinogenemia; Blood Coagulation Disorders; Buttocks; Combined Modality Therapy; Cyclohexanecarbox | 1986 |
A bleeding disorder due to deficiency of alpha 2-antiplasmin.
Topics: Adult; alpha-2-Antiplasmin; Blood Coagulation Disorders; Fibrinolysis; Humans; Male; Tranexamic Acid | 1985 |